Last edition
News about "Ipsen"
Ipsen Discontinues Tazverik for Certain Cancer Uses
In addition to withdrawing Tazverik from the market, Ipsen has initiated steps to stop treatment with tazemetostat for all patients currently enrolled in the ongoing SYMPHONY-1 trial. All participants will receive standard of care, lenalidomide plus rituximab only.
Ipsen | 09/03/2026 | By News Bureau | 144
Ipsen receives positive EMA panel opinion for Ojemda to treat paediatric low-grade glioma
European Medicines Agency’s CHMP recommends conditional approval of Ojemda (tovorafenib) for children with BRAF-altered paediatric low-grade glioma, offering a potential targeted therapy option for relapsed or refractory cases.
Ipsen | 05/03/2026 | By News Bureau | 201
Ipsen and Skyhawk Therapeutics to Work on RNA Targeting Research in Rare Neurological Diseases
Ipsen has signed an exclusive worldwide collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.
Ipsen | 22/04/2024 | By Aishwarya | 477
Biopharmaceutical company Ipsen unveils 52 M Euro expansion plan
The investment is aimed at boosting medicine and ingredient production in cancer and rare disease space
Ipsen | 28/09/2022 | By Sudeep Soparkar | 820
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy